With rapid advancements in molecular technologies, clinicians and researchers use biomarkers to determine their clinical relevance for diagnosis, prognosis, and monitoring of treatment.

What are cancer biomarkers?

Cancer biomarkers are biological molecules linked to cancer that offer valuable insights into its presence, stage, progression, and treatment response. Their detection plays a vital role in clinical diagnostics, enabling early detection, guiding effective treatment strategies, and identifying genetic alterations that indicate a predisposition to certain cancer types.

Importance of cancer biomarkers

Cancer biomarkers play an important role in clinical diagnosis and research. They are essential for:

• Assessing disease risk: Identifying individuals with a predisposition to certain cancers enables early intervention and preventive measures.
• Screening for malignancies: Biomarkers can help screen otherwise healthy individuals for undetected cancers, such as prostate cancer.
• Differentiating cancer types: Biomarkers help in distinguishing between various malignancies and benign conditions, providing clarity in complex diagnoses.
• Determining prognosis and recurrence risk: Biomarkers provide insight into disease progression and recurrence likelihood, using methods like gene expression profiling for personalized prognosis in cancers like breast cancer.
• Monitoring treatment response: Ongoing tracking of biomarkers helps evaluate treatment effectiveness and detect any progression or recurrence of cancer, making them essential for adaptive treatment strategies.
• Predicting treatment response: Biomarkers aid in the selection of optimal therapies, especially in precision oncology (eg, human epidermal growth factor 2 [HER2] for trastuzumab in breast cancer, which is approved for clinical use).
• Guiding therapeutic decisions: They help identify patients potentially benefiting from targeted therapies or immunotherapies, facilitating tailored treatment (eg, programmed death-ligand 1 (PD-L1, approved for clinical use¹) for lung cancer immunotherapy).
• Evaluating minimal residual disease: Some biomarkers, such as circulating tumor DNA (ctDNA, approved for clinical use²) and prostate-specific antigen (PSA, approved for clinical use³) blood tests, detect residual cancer cells after treatment, indicating the need for further intervention.
• Identifying therapeutic resistance: To predict or detect the development of treatment resistance, allowing for alterations in treatment strategies.
• Drug development and research: Cancer biomarkers play a vital role in clinical trials, they assist in identifying appropriate patient populations, monitor responses, and evaluate new treatments.

While some biomarkers are specific to certain applications, others (such as PSA and PD-L1) can serve multiple purposes, making them versatile tools in cancer management.

Types of cancer biomarkers

Cancer is a complex disease driven by genetic and epigenetic changes, with early detection frequently being associated with a better prognosis. Biomarkers like PSA, carcinoembryonic antigen (CEA, approved for clinical use⁴), cancer antigen 125 (CA-125/MUC16, approved for clinical use⁴), exosomes (for example, CD63-positive exosomes contain the breast cancer markers miR-21 [in clinical trial phase]⁵, miR-1246 [currently in the research phase]⁶, and HER2⁷), microRNAs⁸, and circulating tumor cells offer valuable insights for diagnosis and treatment.

Genetic biomarkers

Genetic biomarkers are specific alterations in an individual’s genome that can be used to indicate the presence of a disease, like cancer, and play a vital role in cancer care by guiding the selection of targeted therapy based on the individual's unique genetic profile, whilst also being useful in predicting prognosis and assessing recurrence risks.

These genetic biomarkers include mutation-based markers (such as V-Raf murine sarcoma viral oncogene homolog B (BRAF, approved for clinical use)⁹ for melanoma, epidermal growth factor receptor (EGFR, approved for clinical use)¹⁰ for lung cancer, Kirsten rat sarcoma viral oncogene homolog (KRAS, approved for clinical use)¹¹ for colorectal cancer, and HER2 for breast cancer) and gene-expression profiles in which genetic tests have been developed that can examine, for example, as many as 70 genes to classify patients with breast cancer into high or low-risk categories.

Their application enhances personalized treatment approaches across various cancers, improving diagnosis and patient outcomes.

Protein biomarkers

A protein biomarker is a protein that serves as a biological indicator of a specific condition. Identified through proteomic analyses, these biomarkers—often referred to as proteomic biomarkers—provide insights into protein interactions and modifications. They play an important role in understanding cancer development and progression. Additionally, proteins detected in various body fluids hold promise for the early detection, staging, and monitoring of cancer.

Food and Drug Administration (FDA)-approved protein biomarkers like human chorionic gonadotropin (HCG), alpha-fetoprotein (AFP), and HER2/NEU are already used in clinical practice to stage testicular cancer and improve breast cancer prognosis.

Explore our cancer marker guide for the most common markers of several types of cancer.

Epigenetic biomarkers

Epigenetic alterations, such as DNA methylation and histone acetylation changes, serve as promising biomarkers for cancer due to their stability, specificity to certain genes, and potential for non-invasive detection.

Hypermethylation of tumor suppressor genes (eg, Ras association domain family 1 isoform A (RASSF1A, in clinical trial phase)¹², breast cancer gene 1 (BRCA1, approved for clinical use)¹³, p16, approved for clinical use)¹⁴ and reduced histone H3 acetylation in cancer cells are associated with increased risks of cancers like lung, ovarian, and prostate.

Metabolic biomarkers

Cancer cells exhibit significant metabolic alterations to meet their energetic needs and requirements of materials for growth, allowing them to proliferate rapidly. Metabolic biomarkers, reflecting alterations in metabolic pathways of the cell, provide insights into cancer growth and survival, aiding in diagnosis, prognosis, and treatment.

Key examples of metabolic biomarkers for cancer include:

• Elevated levels of lactate and glucose transporters that are linked to glycolysis.
• Dysregulated TCA cycle intermediates like fumarate and succinate can promote further tumor growth. Specifcially, mutations in the enzymes, fumarate hydratase and succinate dehydrogenase, which respectively convert fumarate to malate and succinate to fumarate in the TCA cycle, are often associated with the accumulation of these oncometabolites in cancer cells¹⁵.
• Markers of altered lipid and amino acid metabolism, such as choline and glutamine, are commonly observed in cancer cells. These cells typically exhibit increased choline uptake and metabolism to support phospholipid synthesis and rely on elevated levels of glutamine as a precursor for nucleotide and amino acid production, as well as an energy source.
• Increased deoxythymidine for nucleotide synthesis which indicates an increased rate of nucleotide production for rapid cell division in cancer cells.

While research strongly indicates the potential of these metabolic biomarkers as prognostic and diagnostic markers of cancer, clinical validation is required for their application.

Cellular biomarkers

Cellular biomarkers are biological molecules produced by the body or tumor that can be used to detect, diagnose, and treat cancer. Biomarkers like circulating tumor cells (CTCs, approved for clinical use)¹⁶ and cell-free DNA (cfDNA, approved for clinical use)¹⁷ serve as valuable cellular biomarkers in advanced cancer stages, providing prognostic insights and guiding treatment decisions, especially in metastatic breast, prostate, and lung cancer. By using molecular diagnostic techniques like DNA and RNA sequencing, CTC counts assist in:

• Predicting patient survival
• Monitoring disease progression
• Assessing the response to therapy

Minimal residual disease biomarkers

Minimal residual disease (MRD) refers to the small number of cancer cells remaining after treatment, and its detection can be used to predict future relapses, guiding treatment decisions. New technologies and biomarkers are enabling personalized treatment approaches based on the biological properties of MRDs, potentially allowing for targeted therapies rather than standard treatments. MRD testing is currently being assessed in a clinical trial¹⁸.

Emerging cancer biomarkers

Emerging cancer biomarkers offer promising new avenues for early detection, personalized treatment, and monitoring of disease progression.

Liquid biopsy-based biomarkers

Analysis of liquid biopsies is a minimally invasive diagnostic method that analyzes components in fluids like blood or urine, such as CTCs, cell-free DNA, and proteins, to detect cancer early and monitor treatment. This technique offers insights into a patient’s molecular profile, helping identify therapeutic targets through genetic and epigenetic information in cfDNA/ circulating tumor DNA (ctDNA) and extracellular vesicles (EVs currently under research) from a patient's blood or other bodily fluids.

• Circulating tumor DNA (ctDNA): ctDNA may serve as an effective non-invasive cancer biomarker that can be detected in the blood and can provide early and accurate insights into disease progression and patient survival¹⁹. ctDNA is small fragments of DNA released from tumor cells that contain tumor-related genomic information. The amount of ctDNA detected varies depending on the type of tumor, its location, and the stage of cancer. Its detection can potentially guide treatment choices and monitor therapy effectiveness and has shown prognostic significance in cancer research. More sensitive detection methods utilizing ctDNA are being developed and are soon expected to be used in clinical applications.

• Exosomes: Exosomes, small extracellular vesicles loaded with active biomolecules, serve as valuable cancer biomarkers and can be used to predict prognosis due to their presence in bodily fluids and the similarity of their contents with a parent cell. Tumor-derived exosomes (TEXs; in the clinical trial phase) are a promising biomarker for cancer diagnosis and prognosis as they contain molecular components that reflect the physiological and pathological status of the tumor cells from which they originated. TEXs contribute to cancer progression by shaping the tumor microenvironment through intracellular communication by transferring oncogenic proteins and genetic materials, and promoting metastasis, angiogenesis, and immunosuppression. Specific exosomal proteins, miRNAs, and long non-coding RNAs have emerged as potential diagnostic markers in various cancers like pancreatic, breast, and gastric cancers. For example, lncRNA PCA3 is approved for clinical use. TEXs can be assessed in non-invasive liquid biopsies to detect the presence of cancer early before clinical symptoms appear.

• MicroRNAs (miRNAs): miRNAs are a group of small non-coding RNAs involved in regulating a range of developmental and physiological processes. Dysregulated expression of several miRNAs is associated with the development of diseases, including cancer. miRNAs are non-invasive biomarkers that can be used to detect cancers that are difficult to diagnose and for subtype classification. A few examples include:

  • miR-18a (currently under research): upregulated in several cancers, including liver cancer, breast cancer, renal cell carcinoma, and ovarian cancer²⁰.
  • miR-34b/c (currently under research): causes cell cycle arrest in uveal melanoma cells and potentially reduces the growth and migration of melanoma cells²¹.
  • miR-155 (currently under research as a cancer biomarker): upregulated in Hodgkin's lymphoma²².
  • miR-206 (in clinical trial phase): downregulated in rhabdomyosarcoma and targets the MET oncoprotein²³.

Immune-related biomarkers

Immune-related biomarkers are measurable substances in the body that can indicate the activity of the immune system or the intensity of a disease. These biomarkers, particularly immune cell infiltration patterns, offer insights into cancer progression and patient prognosis, with tumor-infiltrating lymphocytes and regulatory T-cells (T-regs) serving as key indicators.

• Immune-derived biomarkers: These include peripheral blood cell population counts, various cytokines, and tumor-infiltrating lymphocytes. Additional factors such as cytokines, immune checkpoint molecules (eg, PD-1, approved for clinical use and CTLA-4, approved for clinical use)24, EVs25, tumor mutational burden (TMB, approved for clinical use)26, antigen-specific T cells27, C-reactive protein (CRP, approved for clinical use)28, immunoglobulins29, and various immune cell populations, including natural killer (NK) cells30, dendritic cells31, and regulatory T cells32, can all be measured in the blood or other bodily fluids to assess the immune system's state and potential disease activity.
• Tumor mutational burden (TMB): TMB is defined as the number of mutations per mega-base of genomic sequence. It is an important predictor of immune checkpoint inhibitor efficacy, with panel sequencing now commonly used in clinical practice.
• Immune checkpoint proteins: Immune checkpoint proteins like programmed cell death protein (PD-1) and PD-1 ligand (PD-L1, approved for clinical use)¹ play an important role in regulating immune responses, with PD-1 acting as a "brake" on immune function, suppressing T-cell activity against tumors. Inhibiting the PD-1/PD-L1 pathway has shown potential in reactivating T cells to effectively target and eliminate cancer cells, offering significant therapeutic benefits across various cancers.
• Immunological biomarkers: These include serum cytokines, chemokines, adipocytokines, and soluble forms of cell receptors. They can serve as surrogate markers for cellular activation. A few examples include PD-L1, neopterin (in the clinical trial phase)³³, and CD3 bispecific antibodies (approved for clinical use)³⁴. Regulatory T cells (Tregs) are a type of immune cell that can suppress the body's immune response against cancer. They can accumulate in tumors and the blood of cancer patients. The presence of Tregs in tumors is often associated with a poor prognosis.
• Tumor-derived biomarkers: These include the presence of negative regulatory molecules and dynamic changes in the tumor genome sequence. A few examples include protein-based markers (for example, CEA, CA 125, AFP, and PSA)^35,36,37 genetic markers such as specific mutations in genes like EGFR³⁸ or KRAS³⁹, and liquid biopsy markers such as ctDNA and CTCs⁴⁰.

Multi-omics biomarkers

Multi-omics integration, combining data across genomes, epigenomes, transcriptomes, proteomes, metabolomes, and microbiomes, enables a comprehensive understanding of complex diseases like cancer. This approach enhances insights into the biological processes of cancer as well as outcomes, supporting more effective diagnoses and treatment strategies.

Biomarkers identified using artificial intelligence

Artificial intelligence (AI) and machine learning (ML) enhance cancer research by analyzing large quantities of medical images, genomic data, and patient records to improve early detection, diagnosis, prognostic prediction, and treatment personalization⁴¹. These technologies also aid in drug discovery, precision medicine, and data integration, providing clinicians with data-driven insights for optimized patient care and targeted therapies.

Techniques for cancer biomarker testing and detection

Techniques for cancer biomarker testing and detection include widely used methods like enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR) and immunohistochemistry, along with emerging technologies such as multiplex immunohistochemistry, electrochemical biosensors, and next-generation sequencing, which offer enhanced sensitivity, specificity, and the potential for personalized treatment strategies.

Immunohistochemistry (IHC) is important in breast cancer diagnosis for:

• Distinguishing between ductal and lobular carcinoma
• Evaluating prognostic markers like HER2, hormone receptors, and Ki-67 (approved for clinical use)^42,43
• Undergoing metastatic assessments.

ImmunoPCR combines the specificity of antibodies from ELISA with the amplification power of PCR, resulting in significantly enhanced sensitivity for detecting very low levels of cancer biomarkers. This technique is highly sensitive and can detect low-abundance targets like high mobility group box 1 (HMGB1, in pre-clinical stage)⁴⁴.

Emerging multiplex-based techniques, like multiplex IHC/immunofluorescence (mIHC/IF), allow for the simultaneous detection of multiple markers on a single tissue section; this technique is currently used clinically⁴⁵. mIHC/IF offers high-throughput, standardized analysis, making it a promising tool for cancer research and clinical practice, especially in cancer immunotherapy.

Electron microscopy provides detailed tumor cell structure information. It is used when immunocytochemistry is insufficient and is essential for diagnosing complex cases requiring definitive diagnosis⁴⁶. For instance, the electron microscope can also help in the differential diagnosis of brain tumors, classification of malignant lymphomas, acinar cell carcinomas of the pancreas, and salivary glands as well as in the differential diagnosis of various types of leukemia.

Electron microscopy is typically used clinically after immunostaining procedures have been performed and found to be insufficient. However, there are some cases where electron microscopy is the first choice after routine light microscopy.

Fluorescence in situ hybridization (FISH) uses fluorescently labeled DNA probes to find matching stretches of DNA in tumor cells⁴⁷. The probes glow under a microscope, showing where the probes match the cancer cells. This approach is used clinically to detect gene mutations in cancer.

Radioimmunoassay (RIA) is a highly sensitive laboratory-based method used in biomarker testing to determine the concentration of specific antigens (biomarkers) in samples, such as blood. The technique involves radioactively labeled antibodies that compete with the antigen in the sample to bind to a specific antibody, enabling precise quantification of the biomarker. RIA is used to test for various cancer markers, including carbohydrate antigen 19-9 (CA 19-9, approved for clinical use)⁴⁸ for pancreatic cancer and cancer antigen 15-3 (CA 15-3, approved for clinical use) for breast cancer⁴⁹.

However, the limitations of RIA are significant, such as potential radioactive waste contamination, the need for specialized safety equipment, and potential radiation exposure of workers due to the long incubation time. limit its wide use.

Advanced technologies for biomarker testing

The detection of cancer has traditionally relied on laboratory procedures that use a sample of a patient's tissue, blood, or other bodily fluid to identify the presence of certain molecules, proteins, or genes that may indicate the presence of cancer. Advanced technologies, such as next-generation sequencing and digital PCR⁵⁰, among other new technologies, offer enhanced sensitivity and/or lower detection costs, including those using electrochemical biosensors, such as:

DNA walkers

DNA walkers are nanodevices that can detect cancer biomarkers by amplifying signals and enabling precise detection⁵¹. They are made up of DNA strands and a gold nanorod, and they can be programmed to follow a specific trajectory. They are highly flexible, efficient, and directional, making them well-suited for detecting tumor-derived vesicles. This technique is currently under research.

Hybridization chain reaction (HCR)

HCR is a promising technique for detecting cancer biomarkers because it’s an enzyme-free, isothermal DNA amplification method that can be performed at room temperature⁵². This technique has been used to detect KRAS gene mutations (pancreatic cancer), exosomes released from pancreatic cancer, lncRNAs in clear-cell renal-cell carcinoma, and exosomal miRNAs in clinical urine samples. This technique is being actively developed for its potentially promising application.

Gene editing through clustered regularly interspaced short palindromic repeats (CRISPR/Cas9)

This technique is inspired by prokaryotic immunity and enables precise genome engineering to study cancer-related genes, model tumors, and identify drug targets, significantly advancing cancer research. CRISPR/Cas9 can be used to detect tumor-related targets like ctDNA, CTCs, and TEXs, which are secreted by tumor cells into the blood or other samples. Advanced technology helps reveal mechanisms such as those underlying tumorigenesis and drug resistance and thus holds the potential for improving therapies like adoptive T-cell therapy⁵³. CRISPR/Cas9 is widely being researched for its value.

Innovative methods, such as the use of gold nanocrystals, MXenes (two-dimensional transition metal carbides and nitrides used in electrochemical biosensor development)⁵⁴, and DNAzyme amplification, show promise for ultrasensitive and reproducible ctDNA detection in clinical applications. Advances in nanomaterials, particularly gold nanoparticles, are improving the efficacy of these assays, enhancing their sensitivity and specificity for cancer biomarker detection.

Next-generation sequencing (NGS)

Advances in next-generation sequencing (NGS) have enabled personalized cancer treatments based on molecular profiles, though the optimal use of NGS in clinical settings remains an ongoing challenge.

Rapidly evolving clinical research highlights the importance for physicians to evaluate and apply NGS-based biomarkers and targeted therapies, guided by current clinical evidence.

Genome profiling

Advancements in sequencing technology have made genomic profiling of cancer genes part of routine care, helping classify cancer subtypes, predict responses to therapy, and assess the risk of hereditary cancer. This approach is clinically approved for cancer biomarker testing⁵⁵.

Efforts now focus on combining tumor and germline analyses, identifying mutational patterns, and exploring whole-genome, transcriptome, and cell-free DNA sequencing for more precise, non-invasive cancer monitoring.

Biosensors

Biosensors provide rapid and highly sensitive detection of cancer biomarkers, capable of identifying malignant cells at significantly lower concentrations than traditional methods. This makes them a valuable tool for the early diagnosis of cancer. They operate by converting biological signals, such as DNA, RNA, or proteins, into electrical or digital signals for analysis. Nano-fabricated biosensors are actively being studied and may potentially be used clinically as a point-of-care device for early cancer diagnosis⁵⁶.

Advances in optical sensor designs, two-dimensional materials, and technologies like surface-enhanced Raman spectroscopy and terahertz waves are driving the development of efficient, low-cost, and versatile biosensors for clinical and point-of-care applications for cancer.

Digital PCR and mass spectrometry-based proteomics

Cancer shows significant proteomic diversity and single-cell proteomics (SCP) using mass spectrometry is emerging as a powerful tool to study this diversity⁵⁷. Briefly, SCP involves the isolation of single cells, followed by cell lysis and protein denaturation, digestion, labeling and pooling, peptide identification by mass spectrometry (MS), and then finally, data analysis. SCP technology is primarily used broadly for biomarker discovery, tumor microenvironment analysis, and drug resistance analysis.

This technique is advancing rapidly, providing valuable insights into cancer research, with ongoing developments aimed at addressing research gaps and future applications.

Digital PCR uses PCR that is partitioned into thousands of single partitions. The nucleic acid template is randomly distributed across all available separations and amplified individually. It is more precise and sensitive than traditional PCR methods.

Digital PCR is an ultrasensitive tool for tumor genotyping and liquid biopsy, enabling accurate detection of nucleic acid-based markers from various biological fluids to monitor tumor progression, relapse, and treatment response in cancers like colorectal, lung, and hematological malignancies. While this technique holds promise, it is still in the research phase.

Imaging biomarkers

Imaging biomarkers (IBs) are essential in oncology for monitoring cancer progression or response to treatment using imaging techniques such as CT, MRI, and PET. It helps to identify tumor characteristics by providing detailed images that reveal the size, location, and heterogeneity of tumors, as well as their spread to lymph nodes or other organs. This improves their clinical use, and recommendations focus on validation, cost-effectiveness, and standardization, with IBs aiding in tumor detection and treatment monitoring.

Applications, opportunities, and challenges in cancer biomarker research

Cancer biomarker research offers opportunities for early detection, personalized therapies, and improved treatment monitoring. Still, challenges such as tumor heterogeneity, technical limitations, high costs, and regulatory hurdles remain significant barriers to widespread clinical implementation.

Biomarkers are important in early cancer detection, precision medicine, monitoring treatment response, and drug development, with advancements like liquid biopsies and genomic profiling enabling more personalized and effective cancer care.

Early cancer detection and screening

Early diagnosis of cancer greatly improves survival chances, but existing detection methods face limitations in identifying small cancers. Recent advancements in liquid biopsy, which analyzes biomarkers in body fluids like blood, offer a promising, convenient approach for early cancer detection.

Precision medicine and personalized therapies

Personalized treatment in medicine aims to tailor care to each patient’s unique biology, yet this goal remains challenging due to the complex interplay of factors affecting health and disease. Advances in biomarker discovery and technology are essential to accurately diagnose, monitor, and adjust treatments dynamically, paving the way for more precise, individualized patient care.

Monitoring treatment response and disease progression

Tumor heterogeneity complicates treatment response monitoring, as single-site tumor samples give limited insights due to diverse cell subpopulations. Recent advances in analyzing ctDNA and RNA from blood samples offer a minimally invasive method for real-time monitoring of mutation and gene expression changes.

Drug development and clinical trials

Biomarkers play a vital role in cancer screening, diagnosis, treatment prediction, and disease monitoring, making their evaluation and validation essential for integration into routine clinical care. Their increasing use in oncology, evidenced by a rise in biomarker-based clinical trials, highlights their growing impact on personalized therapies and drug discovery, although challenges remain for cost-effective implementation.

Development of novel targeted therapies

Advances in molecular pathology and next-generation sequencing have increased the number of treatable tumor-specific abnormalities, improving cancer treatments and survival rates.

With more access to genomic profiling, healthcare professionals face the challenge of interpreting complex data, while new methods like transcriptomics and liquid biopsies are expanding precision medicine by offering more ways to identify biomarkers beyond just DNA sequencing.

Cancer risk assessment and prevention

Precision medicine aims to tailor cancer treatment by identifying patients who will respond to specific therapies through the use of diagnostic and prognostic biomarkers. Advances in mechanism-driven, data-driven, and technology-driven biomarker discovery, such as liquid biopsies, are enhancing cancer risk assessment, improving patient stratification, and promoting survival by integrating multiple biomarker types.

Emerging trends and opportunities in cancer biomarker research

Emerging trends in cancer biomarkers include advanced genetic techniques like whole exome sequencing, whole genome sequencing, and RNA sequencing, which provide detailed insights into genetic changes and gene expression in cancer. These methods enhance our understanding of cancer pathways, supporting the development of precise diagnostics and targeted treatments.

Additionally, the integration of multi-omics data provides a more holistic understanding of cancer biology. Complementing these approaches, AI and machine learning technologies are revolutionizing biomarker research by facilitating the development of novel biomarker panels and improving their clinical application, paving the way for personalized and precision oncology.

Integration of multi-omics data

Multi-omics approaches involve the integration of genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomes. It provides valuable opportunities to understand cancer biology from multiple perspectives, revealing cancer subtypes, disease mechanisms, and driver genomic alterations while enhancing tumor classification, diagnostics, and prognostications.

Development of novel biomarker panels

Biomarker discovery through multi-omics data integration and AI offers significant advancements in cancer diagnosis and prognosis. For example, the development of a novel 30-gene biomarker panel using AI-based machine learning accurately predicts poor overall survival and therapy resistance in HPV-negative head and neck squamous cell carcinoma (HNSCC) patients, offering improved patient stratification and personalized treatment approaches.

Artificial intelligence and machine learning applications

AI and ML applications in cancer biomarker research are transforming the understanding of cancer by analyzing complex multi-omics data to improve early diagnosis, prognosis, and treatment strategies, offering new opportunities for more accurate and personalized cancer care.

Standardization of biomarker testing and reporting

Standardizing biomarker testing and reporting is essential for effective clinical implementation, requiring proper study design, integration of prior biological knowledge, and robust validation while overcoming challenges like the uneven maturity of omics approaches and the need for improved assay technologies.

Validation of emerging biomarkers in clinical studies

Validating emerging biomarkers through multi-cohort studies and comprehensive multi-omics datasets is crucial for their clinical relevance. For example - genes like STE20 like kinase (SLK, in the research phase) and 5'-nucleotidase ecto (NT5E, in the clinical trial phase) show strong associations with cancer prognosis and therapy resistance.

Challenges and limitations in biomarker research

Despite several benefits, biomarker research faces challenges such as inadequate animal models, limited predictive biomarkers, high costs, and complex clinical trials, variability in results, lack of standardization, and difficulties in clinical validation hinder further progress.

Biological heterogeneity of tumors

Tumors show two types of genetic diversity:

• Inter-patient heterogeneity - between two patients
• Intra-patient heterogeneity - within individual patients

This heterogeneity complicates the creation of universally effective biomarkers, while their molecular evolution over time and in response to treatment requires ongoing monitoring and adaptation of biomarker strategies.

Technical and biological challenges and limitations

Technical limitations in cancer biomarker detection include challenges such as variations in sample handling, which can affect the reliability of test results, and limitations in assay sensitivity and specificity, which create inconsistencies in biomarker testing for cancer. Profiling techniques also affect reproducibility, further complicating consistent detection across studies.

Integrating multiple omics approaches to improve detection sensitivity and address tumor heterogeneity presents significant limitations. Additionally, complex cancer biology, tumor heterogeneity, and the complexity of developing reliable, specific biomarkers further complicate efforts to identify consistent biomarkers for clinical use.

Reproducibility and validation

Cancer biomarker testing faces challenges with reproducibility and consistency across studies, impacting clinical reliability. Standardization, quality control, and validation in large cohorts are essential steps to ensure biomarkers are accurate, cost-effective, and clinically applicable.

Ethical and regulatory considerations

The clinical implementation of cancer biomarkers is slowed by complex regulatory requirements and ethical issues, particularly in pediatric cases where reference values are limited. Regulatory challenges and ethical considerations, such as patient consent and data privacy, significantly impact the development, approval, and clinical application of cancer biomarkers.

Interdisciplinary collaboration among scientific and clinical fields is essential to overcome these ethical and regulatory challenges effectively.

Cost and accessibility of biomarker testing

The high costs of advanced biomarker detection technologies, such as next-generation sequencing, limit their accessibility in routine clinical practice, and current assays often lack the economic feasibility for use in community-based hospitals.

This issue underscores the need for more affordable and accessible biomarker testing methods to ensure that advances in cancer diagnostics can be translated to broader patient populations.

FAQs

What are the latest advancements in cancer biomarkers?

Recent advancements in cancer biomarkers include the use of liquid biopsy technologies like ctDNA and exosomes for early detection and treatment monitoring. Additionally, next-generation sequencing and AI-driven biomarkers are improving personalized cancer diagnostics and targeted therapies.

Additionally, electrochemical biosensors, such as DNA walkers, hybridization chain reactions, digital PCR, and mass spectrometry-based proteomics are also advancing, allowing for a comprehensive analysis of protein expression profiles linked to cancer progression and therapeutic responses. These technologies collectively represent the future of cancer diagnosis and personalized treatment strategies.

How do genetic biomarkers differ from proteomic biomarkers in cancer detection?

Genetic biomarkers detect mutations or alterations in DNA, providing insights into the genetic basis of cancer, while proteomic biomarkers focus on protein expression changes, reflecting cancer-related cellular processes.

Some genetic markers include mutations in genes like EGFR or KRAS, while a few protein-based markers include EA, AFP, CA 125, and PSA. Both play complementary roles in cancer detection, with genetic biomarkers offering early diagnostic potential and proteomic biomarkers aiding in monitoring disease progression and treatment response.

How are biomarkers used in predicting cancer prognosis?

Biomarkers are used in predicting cancer prognosis by identifying genetic mutations, protein levels, or other molecular features that correlate with disease progression and/or patient survival. They help assess the likelihood of recurrence, treatment response, and overall survival, guiding personalized treatment decisions.

Some examples of prognostic biomarkers include PSA level (prostate cancer) and PIK3CA mutation status (for women with HER2-positive metastatic breast cancer).

What role do epigenetic biomarkers play in cancer diagnosis?

Epigenetic biomarkers facilitate cancer diagnosis by assessing changes in DNA methylation, histone modification, or non-coding RNA expression that are associated with tumorigenesis. These biomarkers can provide insights into cancer-specific alterations and help in early detection, classification, and monitoring of the disease.

A few examples of epigenetic biomarkers in cancer diagnosis include:

• Breast cancer: elevated expression of lysine-specific histone demethylase 1 and circulating miR-21 and miR-10b are associated with aggressive ER-subtype breast cancer.
• Colorectal cancer: DNA methylation analysis of the vimentin (VIM) gene in stool samples is a non-invasive diagnostic test for colorectal cancer.
• Pancreatic cancer: Abnormal DNA methylation of several genes, including NPTX2, may serve as a diagnostic biomarker. Additionally, high serum levels of miR-196a may predict a poor prognosis in pancreatic cancer.

References

1. Wang, Y., Tong, Z., Zhang, W., et al. FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients. Frontiers in oncolog,y 7,683419 (2021)
2. Stadler, J.C., Belloum, Y., Deitert, B., et al. Current and future clinical applications of ctDNA in immuno-oncology. Cancer research, 82, 349-358 (2022)
3. Sundaresan, V.M., Smani, S., Rajwa, P., et al. Prostate-specific antigen screening for prostate cancer: diagnostic performance, clinical thresholds, and strategies for refinement. Urologic oncology, 43, 41-48 (2025)
4. Guidance for submission of tumor marker premarket notifications [510(k)s] to Food and Drug Administration. U.S. Department of Health and Human Services Food and Drug Administration Center for Devices and Radiological Health. 1996; https://www.fda.gov/media/135529/download
5. Jenike, A.E., Halushka, M.K. miR-21: a non‐specific biomarker of all maladies. Biomarker research, 9, 18 (2021)
6. Ghafouri-Fard, S., Khoshbakht, T., Hussen, B.M., et al. A Review on the Role of miR-1246 in the Pathoetiology of Different Cancers. Frontiers in molecular biosciences, 8, 771835 (2022)
7. Jordyn S. FDA approves HER2 test as companion diagnostic for zanidatamab in biliary tract cancer. Targeted oncology. 2024; FDA Approves HER2 Test as Companion Diagnostic for Zanidatamab in Biliary Tract Cancer
8. Metcalf, G.A.D. MicroRNAs: circulating biomarkers for the early detection of imperceptible cancers via biosensor and machine-learning advances.  Oncogene,  43, 2135-2142 (2024)
9. Edward W. Dabrafenib–trametinib combination approved for solid tumors with BRAF mutations. National Cancer Institute. 2022; https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-dabrafenib-trametinib-braf-solid-tumors
10. U.S.F.D.A. FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. 2024; https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-vmjw-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer-indications
11. U.S.F.D.A. FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications. 2024; https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab-kras-g12c-mutated-colorectal-cancer
12. Methylation-specific PCR test for early screening and early diagnosis of nasopharyngeal carcinoma. NCT06367049 2024; https://clinicaltrials.gov/study/NCT06367049
13. Edward W. Olaparib approved for treating some breast cancers with BRCA gene mutations. 2018; https://www.cancer.gov/news-events/cancer-currents-blog/2018/fda-olaparib-breast-brca-mutations
14. Mehanna, H., Taberna, M., von Buchwald, C., et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet oncology, 24, 239-251 (2023)
15. Beyoğlu, D., Idle, J.R. Metabolic rewiring and the characterization of oncometabolites. Cancers (Basel) 13, 2900 (2021)
16. Danila, D.C., Pantel, K., Fleisher, M., et al. Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer journal, 17, 438-450 (2011)
17. Pashtoon, M.K., Benjamin, R.T., Timmy, Q.N., et al. Using cell-free circulating tumor DNA (cfDNA) to identify guideline-relevant biomarkers for therapy selection in 14,000 patients (pts) with metastatic colorectal cancer (mCRC). Journal of clinical oncology, 40 (2022)
18. Medina-Herrera, A., Sarasquete, M.E., Jiménez, C., et al. Minimal residual disease in multiple myeloma: past, present, and future. Cancers (Basel), 15, 3687 (2023)
19. Panet, F., Papakonstantinou, A., Borrell, M., et al. Use of ctDNA in early breast cancer: analytical validity and clinical potential.  npj breast cancer  10, 50 (2024)
20. Kolenda, T., Guglas, K., Kopczyńska, M., et al. Good or not good: role of miR-18a in cancer biology. Reports of practical oncology and radiotherapy, 25, 808-819 (2020)
21. Carvalho, I.N., Reis, A.H., Dos Santos, A.C., et al. A polymorphism in mir-34b/c as a potential biomarker for early onset of hereditary retinoblastoma. Cancer biomarkers, 18, 313-317 (2017)
22. Shao, C., Yang, F., Qin, Z.  et al.  The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis.  BMC cancer,  19, 1103 (2019)
23. Yuan, S., Liu, Z., Yu, S., et al. CCND2 and miR-206 as potential biomarkers in the clinical diagnosis of thyroid carcinoma by fine-needle aspiration cytology. World journal of surgical oncology, 21, 22 (2023)
24. Shen, H., Yang, E.S., Conry, M., et al. Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. Genes & disease, 6, 232-246 (2019)
25. Mathew, M., Zade, M., Mezghani, N., et al. Extracellular vesicles as biomarkers in cancer immunotherapy. Cancers (Basel), 12, 2825 (2020)
26. Sha, D., Jin, Z., Budczies, J., et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer discovery, 10, 1808-1825 (2020)
27. Kalos, M. Biomarkers in T cell therapy clinical trials. Journal of translational medicine, 9, 138 (2011)
28. Fujiwara, Y., Karol, A.B., Joshi, H., et al. C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: a systematic review and meta-analysis. Critical reviews in oncology/hematology, 197, 104352 (2024)
29. Monroy-Iglesias, M.J., Crescioli, S., Beckmann, K., et al. Antibodies as biomarkers for cancer risk: a systematic review. Clinical and experimental immunology, 209, 46-63 (2022)
30. . Gianchecchi, E., Delfino, D.V., Fierabracci, A. Natural killer cells: potential biomarkers and therapeutic target in autoimmune diseases? Frontiers in immunology, 12, 616853 (2021)
31. Zhao, F., Yan, F., Liu, H. New biomarkers based on dendritic cells for breast cancer treatment and prognosis diagnosis. International journal of molecular sciences, 24, 4058 (2023)
32. Zhang, A., Fan, T., Liu, Y.,  et al.  Regulatory T cells in immune checkpoint blockade antitumor therapy.  Molecular cancer,  23, 251 (2024)
33. Melichar, B., Spisarová, M., Bartoušková, M., et al. Neopterin as a biomarker of immune response in cancer patients. Annals of translational medicine, 5, 280 (2017)
34. Firestone, R., Lesokhin, A.M., Usmani, S.Z. An embarrassment of riches: three fda-approved bispecific antibodies for relapsed refractory multiple myeloma. Blood cancer discovery, 4, 433-436 (2023)
35. Zhang, J., Wei, Q., Dong, D., et al. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer. Clinica chimica acta, 523, 19-25 (2021)
36. Wei, Z., Zhang, Y., Lu, H., et al. Serum alpha-fetoprotein as a predictive biomarker for tissue alpha-fetoprotein status and prognosis in patients with hepatocellular carcinoma. Translational cancer research, 11, 669-677 (2022)
37. National Cancer Institute. Prostate-specific antigen (PSA) test. https://www.cancer.gov/types/prostate/psa-fact-sheet
38. Lung Cancer Foundation of America. EGFR. https://lcfamerica.org/about-lung-cancer/diagnosis/biomarkers/egfr/
39. Colorectal Cancer Alliance. KRAS biomarker and colorectal cancer. https://colorectalcancer.org/treatment/types-treatment/why-biomarkers-matter/types-biomarkers/kras-biomarker
40. Wang, X., Wang, L., Lin, H., et al. Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy. Frontiers in oncology, 14, 1303335 (2024)
41. Bhinder, B., Gilvary, C., Madhukar, N.S., et al. Artificial intelligence in cancer research and precision medicine. Cancer discovery, 11, 900-915 (2021)
42. Dowsett, M., Nielsen, T.O., Rimm, D.L., et al. International Ki67 in breast cancer working group. Ki67 as a companion diagnostic: good or bad news? Journal of clinical oncology, 40, 3796-3799 (2022)
43. Davey, M.G., Hynes, S.O., Kerin, M.J., et al. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers (Basel,) 13, 4455 (2021)
44. Liikanen, I., Koski, A., Merisalo-Soikkeli, M., et al. Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. Oncoimmunology, 4, e989771 (2015)
45. Tan, W.C.C., Nerurkar, S.N., Cai, H.Y., et al. Overview of multiplex immunohistochemistry/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun (Lond), 40, 135-153 (2020)
46. Zhou, Y., Tao, L., Qiu, J., et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal Transduction and Targeted Therapy, 9, 132 (2024)
47. Chrzanowska, N.M., Kowalewski, J., Lewandowska, M.A. Use of fluorescence in situ hybridization (fish) in diagnosis and tailored therapies in solid tumors. Molecules, 25, 1864 (2020)
48. Lee, T., Teng, T.Z.J., Shelat, V.G. Carbohydrate antigen 19-9 - tumor marker: past, present, and future. World journal of gastrointestinal surgery, 12, 468-490 (2020)
49. Fu, Y., Li, H. Assessing clinical significance of serum ca15-3 and carcinoembryonic antigen (cea) levels in breast cancer patients: a meta-analysis. Medical science monitor, 22, 3154-3162 (2016)
50. Sancha Dominguez, L., Cotos Suárez, A., Sánchez Ledesma, M., et al. Present and future applications of digital pcr in infectious diseases diagnosis. Diagnostics (Basel,) 14, 931 (2024)
51. Yang, S., Zhu, R., Wang, S., et al. Recent advances in dna-based molecular devices and their applications in cancer diagnosis. Coordination chemistry reviews, 493, 215331 (2023)
52. Cao, X., Dong, J., Sun, R., et al. A DNAzyme-enhanced nonlinear hybridization chain reaction for sensitive detection of microRNA. Journal of biological chemistry, 299, 104751 (2023)
53. Balan, V., Wang, J. The CRISPR system and cancer immunotherapy biomarkers. Methods in molecular biology, 2055, 301-322 (2020)
54. Liu, H., Xing, X., Tan, Y., et al. Two-dimensional transition metal carbides and nitrides (MXenes) based biosensing and molecular imaging. Nanophotonics, 11, 4977-4993 (2022)
55. Liu, H., Xing, X., Tan, Y., et al. Two-dimensional transition metal carbides and nitrides (MXenes) based biosensing and molecular imaging. Nanophotonics, 11, 4977-4993 (2022)
56. . Iqbal, M.J., Javed, Z., Herrera-Bravo, J.,  et al.  Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation.  Cancer cell international,  22, 354 (2022)
57. Tan, Y.C., Low, T.Y., Lee, P.Y., et al. Single-cell proteomics by mass spectrometry: advances and implications in cancer research. Proteomics, 24, e2300210 (2024)